SCHEMBL18101508

SCHEMBL18101508

Cc1cc2ccc3c(N(c4cccc5ccccc45)c4cccc5c4oc4ccccc45)cc(N(c4cccc5ccccc45)c4cccc5c4oc4ccccc45)c4ccc(c1)c2c34

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
KMT2A Q03164 4/20 0.33
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 2/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CYP1A2 P05177 3/20 0.33
MAOA P21397 3/20 0.33
FYN P06241 2/20 0.33
ACHE P22303 2/20 0.33
AHR P35869 2/20 0.33
ERBB2 P04626 1/20 0.33
MAOB P27338 1/20 0.32
ALOX5 P09917 2/20 0.32
LCK P06239 1/20 0.32
ADORA3 P0DMS8 1/20 0.32
MAPT P10636 1/20 0.32
SLC6A2 P23975 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18101524 0.95 KDM4E (0.35) TDP1L3MBTL1KMT2AALDH1A1KDM4E
SCHEMBL18101516 0.91 HPGD (0.33) KMT2AALDH1A1KDM4EGAAHPGD
SCHEMBL18101505 0.88 KDM4E (0.33) KMT2AALDH1A1KDM4EGAAHPGD
SCHEMBL18101593 0.88 TDP1 (0.33) TDP1L3MBTL1KMT2ACYP1A2MAOA
SCHEMBL18101522 0.88 CYP1A2 (0.31) ALDH1A1KDM4EGAAHPGDHSD17B10
SCHEMBL18101507 0.88 LMNA (0.33) ALDH1A1KDM4EGAAHPGDHSD17B10
SCHEMBL18101552 0.88 TDP1 (0.33) TDP1L3MBTL1CYP1A2MAOAFYN
SCHEMBL18798574 0.88 AHR (0.39) TDP1L3MBTL1KMT2AALDH1A1KDM4E
SCHEMBL18101518 0.87 MAOB (0.34) KMT2AALDH1A1KDM4EGAAHPGD
SCHEMBL18101517 0.87 ALOX5 (0.36) ALDH1A1KDM4EGAAHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3196198-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING SAME Idemitsu Kosan Co., Ltd (JP) 2017-07-26 EP disclosed
US-20160284998-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE OBTAINED BY USING SAME IDEMITSU KOSAN CO., LTD. (JP) 2016-09-29 US disclosed
US-20160284998-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE OBTAINED BY USING SAME IDEMITSU KOSAN CO., LTD. (JP) 2016-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160284998-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE OBTAINED BY USING SAME EPB41, RPS4X, OR10J3 TDP1 3706/4885L3MBTL1 1745/4885KMT2A 2273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.